Table 1.
Characteristics of 676 HIV-infected patients initiating outpatient HIV medical care at the University of Alabama at Birmingham (UAB) 1917 and University of Washington (UW) Harborview Clinics, January 2007 – September 2010.
| Characteristic | Overall sample (N=676) | Patients with 2-years follow-up (N=258) |
|---|---|---|
| Age (years) | 35.8 ± 10.8 | 37.1 ± 10.3 |
|
| ||
| Sex × Race/ethnicity | ||
| Non-white Female | 88 (13.3%) | 31 (12.2%) |
| Non-white Male | 289 (43.7%) | 109 (42.9%) |
| White Female | 31 (4.7%) | 15 (5.9%) |
| White Male | 253 (38.3%) | 99 (39.0%) |
|
| ||
| Health insurance | ||
| Private | 245 (37.6%) | 96 (39.8%) |
| Public | 174 (26.7%) | 62 (25.7%) |
| Uninsured | 232 (35.6%) | 83 (34.4%) |
|
| ||
| Site | ||
| UAB 1917 Clinic | 417 (61.7%) | 147 (57.0%) |
| UW Harborview Clinic | 259 (38.3%) | 111 (43.0%) |
|
| ||
| Baseline plasma HIV RNA (log10 c/mL) | 4.56 (0.97) | 4.72 (0.94) |
|
| ||
| Baseline CD4+ T lymphocyte count (cells/μL) | 337 ± 255 | 334 ± 250 |
| <200 cells/μL | 215 (32.8%) | 81 (32.4%) |
| 200-350 cells/μL | 158 (24.1%) | 65 (26.0%) |
| >350 cells/μL | 282 (43.1%) | 104 (41.6%) |
|
| ||
| “No show” visits | ||
| Zero | 363 (53.7%) | 80 (31.0%) |
| One | 144 (21.3%) | 53 (20.5%) |
| ≥ Two | 169 (25.0%) | 125 (48.4%) |
|
| ||
| Initiate antiretroviral therapy | 536 (79.3%) | 224 (86.8%) |
|
| ||
| Achieve plasma HIV RNA <50 c/mL | 425 (62.9%) | 208 (80.6%) |
|
| ||
| 2-year visit adherence | N/A | 0.84 ± 0.16 |
| 0-79% | 83 (32.2%) | |
| 80-99% | 95 (36.8%) | |
| 100% | 80 (31.0%) | |
|
| ||
| 2-year viremia copy years (log10 copy × years/mL) | N/A | 4.31 ± 0.76 |
Data are presented as mean ± standard deviation or frequency (column percent).
Baseline plasma HIV RNA and CD4+ T lymphocyte count measurements were the value on the date nearest the initial clinic visit date within a window of -180 to +7 days; median ± interquartile range of -3 (-23, 0) and -5 (-23, 0) days, respectively, from initial visit date.
“No show” visits: for the overall sample this represents a count with patients censored at first of plasma HIV RNA <50 c/mL or administrative censoring; for the patients with 2-years follow-up (n=258) this represents a count of no show visits during the first 2 years from clinic entry.
Missing data for overall sample and patients with 2 years follow-up: race/ethnicity (n=8, 4), health insurance (n=25, 17), baseline CD4+ T lymphocyte count (n=21, 8), respectively.